Marten Hornsveld, Cinthya Del Angel Zuvirie, Peter van Schaik, Hester Bange, Xena van den Haak, Lama Alhaj Hasan, Steven Ly, Lenno Krenning, Ludovic Bourre, Marrit Putker
Antibody-drug conjugates (ADCs) are a cutting-edge approach in targeted cancer therapy, combining the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapeutic agents.
In vitro efficacy testing is a critical step in ADC development and requires models that exhibit physiological human target-protein expression, growth factor signaling and DNA damage responses to allow for accurate predictions of efficacy. This study highlights the value of performing functional assays for preclinical ADC development.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2024-11-04
2024-10-21
landing_page
15th World ADC San Diego 2024